Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Shixue Chen"'
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Accumulating evidence has revealed that the gut microbiota influences the effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. As a part of the human microbiome, Helicobacter pylori (H. pylori) was reported to
Externí odkaz:
https://doaj.org/article/4b9ea312f0034c68a906025e8cdb49f8
Publikováno v:
Frontiers in Chemistry, Vol 10 (2022)
5-Hydroxymethylfurfural (5-HMF) as a triply catalytic product is a value-added refining chemical in industry production. 5-HMF as biomass feedstock enables to be transformed into other high-value industrial compounds, such as 2,5-furandicarboxylic ac
Externí odkaz:
https://doaj.org/article/00489586efe046c1987ceb5363741a10
Autor:
Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui, Di Huang, Ziwei Huang, Zhaozhen Wu, Yi Hu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have demonstrated promise in treating a variety of advanced cancers; however, little is known regarding their efficacy under various clinical situations, including different canc
Externí odkaz:
https://doaj.org/article/1801b9ad9444452695e68d00dc51d1c9
Autor:
Zhaozhen Wu, Pengfei Cui, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Shixue Chen, Ziwei Huang, Xuan Zheng, Di Huang, Yi Hu
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 15 (2021)
Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 mutation. Further studies suggest that PARP inhibitors (PARPi) can also exhibit e
Externí odkaz:
https://doaj.org/article/72109329fc2f4ade92510cf62f934219
Publikováno v:
Frontiers in Chemistry, Vol 8 (2020)
Externí odkaz:
https://doaj.org/article/dedbcc1e02004a7fa37b29f2019c724b
Publikováno v:
Frontiers in Chemistry, Vol 8 (2020)
The general synthesis methods of bioflavonoid–metal complexes are considered to be unreliable due to the instability of flavonoids in air-saturated alkaline solutions. In this study, dihydromyricetin (DHM), as a representative bioflavonoid, was sel
Externí odkaz:
https://doaj.org/article/236047a9e3764b428819445a91d12b2d
Autor:
Pengfei Cui, Di Huang, Zhaozhen Wu, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Ziwei Huang, Shixue Chen, Xuan Zheng, Yi Hu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Cutaneous adverse events (AEs) have been positively associated with immune checkpoint inhibitor (ICI) efficacy in patients with melanoma, but little is known regarding the association between checkpoint inhibitor pneumonitis (CIP) and pro
Externí odkaz:
https://doaj.org/article/0bb85cf3f39a47d3b9ee87328f9b1da6
Publikováno v:
Journal of Immunology Research, Vol 2019 (2019)
Bispecific antibodies (BsAbs) are a sort of dual functional proteins with specific binding to two distinct targets, which have become a focus of interest in antibody engineering and drug development research and have a promising future for wide appli
Externí odkaz:
https://doaj.org/article/1b42c271283b4c44b1cf5a735ea90eba
Publikováno v:
ChemistryOpen
ChemistryOpen, Vol 10, Iss 4, Pp 503-514 (2021)
ChemistryOpen, Vol 10, Iss 4, Pp 503-514 (2021)
The pyrogallol autoxidation method has been widely utilized to evaluate various antioxidants in antioxidative bioactivities. However, this method is generally not appropriate for estimating the .O2 − radical scavenging capacity of bioflavonoids, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f694705115c9270f99f65f24d535e57
http://europepmc.org/articles/PMC8080285
http://europepmc.org/articles/PMC8080285
Autor:
Zhefeng Liu, Shixue Chen, Jinliang Wang, Sujie Zhang, Junxun Ma, Zhaozhen Wu, Huang Di, Haitao Tao, Xuan Zheng, Yi Hu, Pengfei Cui, Xiao Wang, Ruixin Li, Ziwei Huang
Publikováno v:
Cancer Immunology, Immunotherapy
Background Rationale exists for combining immune checkpoint inhibitors and PARP inhibitors (PARPi), and results of clinical trials in ovarian cancer are promising, but data in other cancers are limited. Method Efficacy and safety of PARPi/anti-PD-1 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad5f50ecc17a94d1fd5b9e3ba94d5a7
http://europepmc.org/articles/PMC8423634
http://europepmc.org/articles/PMC8423634